Navigation Links
Growth factor TGF-B helps maintain health of retinal blood vessels
Date:4/7/2009

Scientists at Schepens Eye Research Institute have found that the growth factor known as TGF-β is essential to the health of blood vessels in the retina and that blocking it can cause retinal dysfunction. These findings, published in the April 2 issue of PLoS ONE, may have an important impact on the prevention and treatment of diseases such as diabetic retinopathy and macular degeneration.

"These results are significant because they add to our understanding of the molecules that help to maintain blood vessels in a healthy state," says Patricia D'Amore, PhD, senior scientist at Schepens and principal investigator of the study, who adds that this information may be useful in understanding the changes that occur in the retinal microvasculature prior to the development of proliferative diabetic retinopathy.

"Insight into the role of this growth factor may also help clinicians monitor the use of systemic drugs targeting TGF-β, which is elevated in a number of conditions (such as cancer and fibrotic diseases) to limit any vision problems that might occur as a side effects." adds Tony Walshe, PhD, the first author of the study and a Postdoctoral Fellow in the D'Amore's laboratory team.

Capillaries are the smallest blood vessels in the body and the site at which oxygen and nutrients are transferred from the blood to the tissues. A capillary is composed of an endothelial cell, which forms the lining of the small tube, and a pericyte, which wraps around the outside of the tube. Scientists have long believed that communication between these two cell types is necessary to maintain blood vessel structure and function.

According to Walshe, the goal of the PLoS ONE study was to determine if TGF-β plays a role in keeping blood vessels functioning normally. In previous experiments using tissue cultures, the D'Amore laboratory had identified TGF-β as a protein that results from the communication between the two cell types and which they use to maintain the health of the small blood vessels. In the current study, the team wanted to confirm that finding in animals.

To do that, they injected mice with a virus that produces large quantities of soluble endoglin, a protein that would circulate, and then bind to and inhibit TGF-β. When they examined the retinas of treated mice, the team found clear evidence that retinal blood vessels were losing their integrity-blood was not moving efficiently through the smaller vessels into the retina tissue, and fluid was leaking out of the vessels, which does not happen when the vessels are functioning properly. These defects led to the death of ganglion cells (nerve cells in the innermost part of the retina) and a loss of visual function.

According to D'Amore and Walshe, the demonstration of the role played by TGF-β is one more piece of a very complex set of controls that keeps blood vessels and the retina healthy.

Future studies are aimed at exploring what other molecules are involved in maintaining healthy blood vessels and how these relate to the development of microvascular diseases.


'/>"/>

Contact: Patti Jacobs
pjacobs12@comcast.net
617-864-2712
Schepens Eye Research Institute
Source:Eurekalert

Related medicine news :

1. Highlights of Economic and Business Growth in the Tampa Bay Region (News Briefs)
2. From Early Brain Development to Digestive Health, New Juicy Juice Beverages Aid Children Through Different Stages of Growth and Development
3. Kenyan Pharmaceutical Industry Can Expect Significant Growth Despite Global Conditions, Finds Frost & Sullivan
4. Cancer stem cells generated by cancer outgrowth
5. Varian Medical Systems to Celebrate Tenth Anniversary and Decade of Growth
6. Veterinary Specialist's Business Growth A Bright Spot in Dull Economy
7. Gerresheimer Achieves Solid Growth in Core Markets - Outlook Confirmed
8. CitiusTech Launches Vantage 2012 Program to Enable Healthcare ISVs to Meet CCHIT Requirements & Capture HITECH Act Related Growth Opportunities
9. Blood protein may hold key to stopping tumor growth in cancer patients
10. Organic Left Standing as the Gold Standard for Consumers Looking to Avoid Food Produced With Synthetic Growth Hormones
11. Coalition of Business, Labor, Academia and Bioscience Groups to Promote Medical Innovation, Spark Economic Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... with extensive sequencing and genomics experience, as Vice President of North American Capital Sales ... be responsible for leading the sales team in the commercialization of the HTG EdgeSeq ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology: